公司本次受让中药创新药柴芩宁神颗粒临床试验批件和发明专利等相关技术，有利于公司快速拓展公司 中药创新药研发管线，加快公司新产品研发进度，提高公司的核心竞争力和可持续发展能力，符合公司 的发展战略以及全体股东的利益。本次协议签订后，因各事项的推进时间较长,存在不确定性，短期内 不会对公司经营业绩产生重大影响。 亚宝药业（600351）(600351.SH)发布公告，公司于2025年8月4日与山西省中医药研究院(简称"山西省中 医院")签署了中药新药项目技术转让协议。公司以人民币2200万元受让山西省中医院拥有的中药1.1类 新药"柴芩宁神颗粒"的临床试验批件、专利权及相关技术资料。 ...

Group 1 - The company has approved a share repurchase plan at the 2024 annual general meeting, with a total repurchase fund of no less than RMB 50 million and no more than RMB 100 million, at a price not exceeding RMB 6.95 per share [1] - The repurchase period is set for a maximum of 6 months from the date of approval, with funds sourced from the company's own and raised funds [1] - As of July 31, 2025, the company has repurchased a total of 200,000 shares, accounting for 0.03% of the total share capital, with a total payment of RMB 1,260,000 at a maximum and minimum transaction price of RMB 6.30 per share [1] Group 2 - The company will adhere to relevant regulations during the repurchase period and will make repurchase decisions based on market conditions, ensuring timely information disclosure [2]

Group 1 - The core point of the article is that Yabao Pharmaceutical announced a share buyback program, having repurchased a total of 200,000 shares as of July 31, 2025, which represents 0.03% of the company's total share capital [2] Group 2 - The share repurchase was conducted through centralized bidding transactions [2] - The announcement was made on the evening of August 1 [2] - The buyback program is part of the company's strategy to enhance shareholder value [2]

亚宝药业集团股份有限公司 证券代码：600351 证券简称：亚宝药业 公告编号：2025-028 亚宝药业集团股份有限公司（以下简称"公司"）于 2025 年 5 月 16 日召开 了 2024 年年度股东大会，审议通过了《关于以集中竞价交易方式回购股份方案的 议案》，同意公司以集中竞价方式回购公司股份，回购股份的资金总额不低于人民 币 0.5 亿元（含）且不超过人民币 1 亿元（含），回购股份价格不超过人民币 6.95 元/股，回购用途为全部予以注销并减少公司注册资本，回购期限为自股东大会审 议通过回购方案之日起不超过 6 个月，本次回购资金来源为公司自有资金及自筹 资 金 。 具 体 内 容 详 见 公 司 于 2025 年 5 月 17 日 在 上 海 证 券 交 易 所 网 站 （www.sse.com.cn）及《中国证券报》《上海证券报》上发布的《亚宝药业集团股 份有限公司关于以集中竞价交易方式回购股份的回购报告书》（公告编号： 2025-020）。 二、回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，公司在回购期间应当在每个月 ...

Group 1 - The company, Yabao Pharmaceutical (600351.SH), announced that as of July 31, 2025, it has repurchased a total of 200,000 shares through centralized bidding, accounting for 0.03% of the company's total share capital [1] - The highest and lowest transaction price for the repurchased shares was 6.30 RMB per share, indicating a stable price point during the buyback [1] - The total amount paid for the share repurchase was 1.26 million RMB, excluding transaction fees, reflecting the company's commitment to returning value to shareholders [1]

(责任编辑：宋政 HN002) 格隆汇8月1日｜A股市场中药股逆势上涨，其中，生物谷涨近25%，维康药业20CM涨停，新光药业 (300519)涨13%，大唐药业涨近11%，天目药业(600671)、新天药业(002873)、太龙药业(600222)、奇正 藏药(002287)、贵州百灵(002424)10CM涨停，众生药业(002317)涨超8%，亚宝药业(600351)、沃华医药 (002107)涨超6%。 | 代码 | 名称 | 涨幅% ↓ | 总市值 | 年初至今涨幅%。 | | --- | --- | --- | --- | --- | | 833266 | 生物谷 | 24.91 | 17.60亿 | 51.12 | | 300878 | 维康药业 | 20.00 | 37.10亿 | 71.51 | | 300519 | 新光药业 | 13.04 | 31.76亿 | 52.71 | | 836433 | 大唐药业 | 10.76 | 22.14亿 | 42.65 | | 600671 | 天目药业 | 10.03 | 18.71亿 | 74.94 | | 002873 | 新天药业 | 10. ...

MACD金叉信号形成，这些股涨势不错！ 格隆汇8月1日｜A股市场中药股逆势上涨，其中，生物谷（维权）涨近25%，维康药业（维权）20CM 涨停，新光药业涨13%，大唐药业涨近11%，天目药业、新天药业、太龙药业、奇正藏药、贵州百灵 （维权）10CM涨停，众生药业涨超8%，亚宝药业、沃华医药（维权）涨超6%。 | 代码 | 名称 | 涨幅% ↓ | 总市值 | 年初至今涨幅% | | --- | --- | --- | --- | --- | | 833266 | 生物谷 | 24.91 | 17.60亿 | 51.12 | | 300878 | 维康药业 | 20.00 | 37.10亿 | 71.51 | | 300519 | 新光药业 | 13.04 | 31.76 乙 | 52.71 | | 836433 | 大唐药业 | 10.76 | 22.14亿 | 42.65 | | 600671 | 天目药业 | 10.03 | 18.71亿 | 74.94 | | 002873 | 新天药业 | 10.03 | 29.19亿 | 27.68 | | 600222 | 太龙药业 | 10.00 | 39.14 ...

（文章来源：每日经济新闻） 每经AI快讯，8月1日，午后中药板块持续逆势拉升，天目药业、华森制药涨停，生物谷一度触及30%涨 停，新光药业、大唐药业涨超10%，亚宝药业、沃华医药、陇神戎发、粤万年青等跟涨。 ...

Group 1 - The A-share traditional Chinese medicine sector is experiencing a significant upward trend, with companies like Tianmu Pharmaceutical and Huasen Pharmaceutical hitting the daily limit increase [1] - Biotech Valley reached a peak of 30cm limit increase, indicating strong market interest and investor confidence [1] - Other companies such as New Light Pharmaceutical and Datang Pharmaceutical saw increases of over 10%, reflecting a broader positive movement in the sector [1] Group 2 - Additional companies including Yabao Pharmaceutical, Wohua Pharmaceutical, Longshen Rongfa, and Guangdong Wannianqing also showed gains, contributing to the overall bullish sentiment in the traditional Chinese medicine market [1]

Core Viewpoint - A nationwide price governance action for traditional Chinese medicine (TCM) is being implemented across multiple provinces in China, addressing the issue of inflated prices and the pressure it places on medical insurance funds [2][9]. Price Governance Action - Provinces such as Guangxi, Liaoning, Heilongjiang, and Tianjin have announced price governance measures for TCM, with additional provinces like Ningxia, Inner Mongolia, Shanxi, Henan, Hebei, and Jilin also participating [2]. - The governance is a response to the significant price discrepancies and the pressure on medical insurance funds caused by high TCM prices [2][11]. Price Discrepancies - Notable TCM products, including An Gong Niu Huang Wan and Ban Lan Gen Granules, have been identified with price differences exceeding 100 times between various manufacturers [3][4]. - A study indicated that out of 93 high-priced TCM products, only 6 had prices close to their theoretical retail prices, highlighting widespread price inflation [3]. Factors Contributing to Price Differences - Price variations are attributed to differences in ingredients, dosage forms, quality standards, and insufficient market competition, leading to concentrated pricing power among certain products [7][11]. - For instance, the daily treatment cost of An Gong Niu Huang Wan can reach 1,898 yuan in Inner Mongolia, significantly higher than the lowest price available [4]. Regulatory Measures - The National Medical Insurance Administration has initiated measures to regulate high-priced TCM products, requiring provinces to verify and adjust prices by July 31 [9][10]. - Provinces have been instructed to impose penalties on companies that fail to comply with price adjustments, including procurement risk identification and potential suspension of product listings [10]. Impact on Pharmaceutical Companies - The price governance affects various pharmaceutical companies, including well-known listed firms such as Taiji Group and Yabao Pharmaceutical, which are now under scrutiny for their pricing practices [12]. - Companies are expected to adapt to a new pricing model based on cost and efficacy, as reliance on high pricing and marketing strategies may no longer be sustainable [13]. Benefits for Patients - The price governance is anticipated to reduce the financial burden on patients, particularly for commonly used medications for chronic diseases, promoting fairer drug pricing and usage [13]. - Increased price transparency is expected to help regulate prescription practices and reduce the misuse of high-priced medications [13].